The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) NonCurrent Deferred Liabilities: BDT0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBNSINA The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
21 GF Score
Price BDT327.10
View Full Analysis

What is The IBN SINA Pharmaceutical Industry NonCurrent Deferred Liabilities?

The IBN SINA Pharmaceutical Industry DHA:IBNSINA +0.06% 21 NonCurrent Deferred Liabilities is BDT0.00 Mil as of . 20. GuruFocus rates DHA:IBNSINA with a GF Score™ of 21/100.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

The IBN SINA Pharmaceutical Industry's non-current deferred liabilities for the quarter that ended in . 20 was BDT0.00 Mil.

The IBN SINA Pharmaceutical Industry NonCurrent Deferred Liabilities Related Terms

The IBN SINA Pharmaceutical Industry NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for The IBN SINA Pharmaceutical Industry's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The IBN SINA Pharmaceutical Industry NonCurrent Deferred Liabilities Chart

The IBN SINA Pharmaceutical Industry Annual Data
Trend
NonCurrent Deferred Liabilities

The IBN SINA Pharmaceutical Industry Semi-Annual Data
NonCurrent Deferred Liabilities
DHA:IBNSINA
21GF Score
The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of BDT0.00 Mil mean?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a NonCurrent Deferred Liabilities of BDT0.00 Mil as of . 20. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on The IBN SINA Pharmaceutical Industry and its competitors.
Is The IBN SINA Pharmaceutical Industry's NonCurrent Deferred Liabilities too high?
The IBN SINA Pharmaceutical Industry's current NonCurrent Deferred Liabilities is BDT0.00 Mil. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's NonCurrent Deferred Liabilities compare to IMNPQ?
The IBN SINA Pharmaceutical Industry's NonCurrent Deferred Liabilities of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. The IBN SINA Pharmaceutical Industry's current NonCurrent Deferred Liabilities is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a current NonCurrent Deferred Liabilities of BDT0.00 Mil. The current NonCurrent Deferred Liabilities is BDT0.00 Mil. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current NonCurrent Deferred Liabilities is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The IBN SINA Pharmaceutical Industry Business Description

Address Mirpur Road, Tanin Center, 3 Asad Gate, Mohammadpur, Dhaka, BGD, 1207
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
21GF Score

Get the complete analysis for DHA:IBNSINA

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT327.10
Price